8月28日，康缘药业跌5.05%，截至发稿，报17.10元/股，成交1.87亿元，换手率1.90%，总市值96.81亿 元。 财通科创主题灵活配置混合(LOF)（501085）基金经理为张胤。 截至发稿，张胤累计任职时间4年159天，现任基金资产总规模10.9亿元，任职期间最佳基金回报 45.37%， 任职期间最差基金回报-23.93%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，江苏康缘药业股份有限公司位于江苏省连云港市经济技术开发区江宁工业城，成立日期1996 年5月8日，上市日期2002年9月18日，公司主营业务涉及涉及药品的研发、生产与销售。主营业务收入 构成为：注射液34.40%，口服液22.46%，胶囊20.28%，片丸剂8.34%，颗粒剂、冲剂7.55%，贴剂 5.04%，凝胶剂1.10%，其他(补充)0.84%。 从基金十大重仓股角度 数据显示，财通基金旗下1只基金重仓康缘药业。财通科创主题灵活配置混合(LOF)（501 ...

Group 1 - The A-share chemical pharmaceutical sector experienced a sharp rise followed by a decline on August 28, with notable drops in stocks such as Nanxin Pharmaceutical and Rejing Bio, both falling over 10% [1] - Other companies in the sector, including Shutaishen, Yuandong Bio, Kanghong Pharmaceutical, and Kangyuan Pharmaceutical, also saw declines [1]

Core Insights - Jiangsu Kangyuan Pharmaceutical Co., Ltd. reported a revenue of 1.642 billion yuan and a net profit of 142 million yuan for the first half of 2025, despite facing complex external environments and fluctuations in drug demand [1] Group 1: Traditional Chinese Medicine Innovation - The core business segment of Kangyuan Pharmaceutical, traditional Chinese medicine (TCM) research, achieved dual breakthroughs in approvals and clinical progress, with 214 drug production licenses obtained, including 50 exclusive varieties [2] - Notable TCM innovations include the approval of Yunu Jian granules for digestive system diseases and clinical trial approvals for Lian Shen Menopausal granules and Gu Ben Xiao Zhen granules, expanding the company's offerings in gynecology and dermatology [2] - Several TCM drugs are in critical clinical stages, with Su Xin Tong Qiao granules and Shuang Yu granules entering the Pre-NDA stage, targeting allergic rhinitis and influenza, respectively [2] Group 2: Chemical and Biological Drugs - In the chemical and biological drug sectors, Kangyuan Pharmaceutical made significant progress in innovative drugs targeting major diseases, focusing on unmet clinical needs in cardiovascular, neurological, metabolic, and autoimmune areas [4] - The Alzheimer's treatment drug Fluoropropylamine tablets has completed Phase II clinical data collection and is expected to start Phase III trials in 2025 [4] - The company is also advancing several other drugs in clinical stages, including those for benign prostatic hyperplasia and acute ischemic stroke [4] Group 3: International Expansion and Technological Empowerment - Kangyuan Pharmaceutical achieved breakthroughs in overseas business, obtaining two natural health product licenses in Canada and two proprietary Chinese medicine licenses in Hong Kong, enhancing the internationalization of TCM [6] - The company is committed to accelerating TCM registration in multiple countries, positioning overseas markets as potential growth points [6] - The establishment of research platforms, including a national key laboratory for TCM manufacturing process control, has led to the approval of five national projects and the filing of 80 invention patents during the reporting period [7]

每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ （记者 张喜威） 每经AI快讯，康缘药业8月28日发布半年度业绩报告称，2025年上半年营业收入约16.42亿元，同比减少 27.29%；归属于上市公司股东的净利润约1.42亿元，同比减少40.12%；基本每股收益0.25元，同比减少 39.02%。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月27日，康缘药业发布公告称，2025年上半年实现营业 收入16.42亿元，同比下降27.29%；归属于上市公司股东的净利润为1.42亿元，同比下降40.12%；归属 于上市公司股东的扣除非经常性损益的净利润为1.2亿元，同比下降45.63%。 ...

Summary of Key Points Core Viewpoint - Kangyuan Pharmaceutical (600557) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its business performance [1]. Financial Performance - The company achieved an operating revenue of 1.642 billion yuan, representing a year-on-year decrease of 27.29% [1]. - The net profit attributable to shareholders was 142 million yuan, down 40.12% compared to the previous year [1]. - The basic earnings per share stood at 0.25 yuan [1].

公司代码：600557 公司简称：康缘药业 江苏康缘药业股份有限公司 2025 年半年度报告 2025 年 8 月 江苏康缘药业股份有限公司（股票代码：600557） 2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人高海鑫、主管会计工作负责人江锁成及会计机构负责人（会计主管人员）李清 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告如涉及未来计划等前瞻性陈述，或会根据市场环境相应调整，该计划不构成公司对投 资者的实质承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-030 江苏康缘药业股份有限公司 关于 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）根据上海证券交易所发布 的《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》的相关要求， 现将公司 2025 年半年度主要经营数据披露如下： 一、2025 年 1-6 月公司主营业务分行业、分产品、分地区经营情况 单位：元 币种：人民币 | | | | 主营业务分行业情况 | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利 率（%） | 营业收入 比上年同 期增减 | 营业成本 比上年同 期增减 | 毛利率比上年同期 增减（%） | | | | | | （%） | （%） | | | 工业销售 | 1,623,380,051.40 | 467,008,495.59 | 71.23 | ...

南财智讯8月27日电，康缘药业发布2025年半年度报告，报告期实现营业收入16.42亿元，同比下降 27.29%；归属上市公司股东的净利润1.42亿元，同比下降40.12%；扣除非经常性损益后的归属于上市公 司股东的净利润1.2亿元，同比下降45.63%；基本每股收益0.25元。 ...

Investment Rating - The investment rating for the industry is "Positive" and is maintained [8]. Core Insights - The innovation layout of traditional Chinese medicine (TCM) companies includes two main categories: (1) TCM new drugs primarily classified as Class 1, which cannot currently use the same valuation system as innovative drugs due to differences in input-output, release rhythm, and lifecycle; (2) Innovative chemical and biological drugs, which are in need of value reassessment within TCM companies [2][6]. - The approval of TCM new drugs is accelerating, but the industry is still in its early development stage. From 2017 to 2024, the approval of TCM new drugs shows an accelerating trend, and with the implementation of policies and active corporate layouts, a surge in TCM new drug listings is expected [6][17]. - Several TCM companies are actively laying out innovative chemical and biological drugs, with companies like Jiuzi Tang, Kangyuan Pharmaceutical, Yiling Pharmaceutical, and Tianshili having multiple pipelines entering clinical stages, laying a solid foundation for long-term development [6][21]. Summary by Sections TCM New Drug Approval - The approval of TCM new drugs is showing an accelerating trend, indicating a potential future surge in listings due to supportive policies and active corporate strategies [6][17]. - The industry is still considered to be in its early development stage, with a different valuation system compared to chemical and biological drugs [6][17]. Innovative Drug Layout of TCM Companies - TCM companies are increasingly involved in the layout of innovative chemical and biological drugs, with several companies having multiple pipelines in clinical stages [21][22]. - Specific companies such as Jiuzi Tang focus on stem cell drugs, while Kangyuan Pharmaceutical has several pipelines in late-stage clinical trials for major diseases [21][22]. - Yiling Pharmaceutical has innovative chemical drugs entering the harvest stage, and Tianshili is involved in various fields including dual antibodies and stem cell injections [21][22]. Investment Perspective - The report suggests that the "insurance fund's transformation" will continue to evolve, with innovative drugs being a primary investment focus. Companies with healthy cash flow and innovative capabilities are favored [28]. - The report emphasizes the importance of breakthrough therapies and technological advancements, particularly in new treatment areas such as cytokine immunotherapy and PD1-based therapies [28].